SINGAPORE--China's Eddingpharm has been granted rights by Amarin ($AMRN) to sell hypertriglyceridemia drug Vascepa icosapent ethyl in Greater China. The deal includes significant milestones, and Amarin will be supplying the drug with Eddingpharm handling any clinical trial work needed on the mainland.
Amarin receives a $15 million upfront payment in the deal and is eligible for $154 million in regulatory and sales milestones as well as tiered double-digit royalties.
Vascepa has been approved in the U.S. as therapy to reduce triglyceride levels in adults with severe hypertriglyceridemia.
- read the release